Circadian pharmacokinetics of mycophenolic acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients

Transplantation

Volumn 82, Issue 4, 2006, Pages 486-493

  Satoh, Shigeru ^a   Tada, Hitoshi ^a   Murakami, Miho ^b   Tsuchiya, Norihiko ^a   Li, Zhenhua ^a   Numakura, Kazuyuki ^a   Saito, Mitsuru ^a   Inoue, Tadamitsu ^a   Miura, Masatomo ^a   Hayase, Yukitoshi ^b   Suzuki, Toshio ^a   Habuchi, Tomonori ^a  

^a AKITA UNIVERSITY   (Japan)

^b HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Acute rejection; Chronopharmacokinetics; Diarrhea; MDR1 C3435T polymorphism; Mycophenolate mofetil; Mycophenolic acid

Indexed keywords

MYCOPHENOLIC ACID; TACROLIMUS;

ABDOMINAL PAIN; ACUTE GRAFT REJECTION; ADULT; AGED; ALLELE; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MULTIDRUG RESISTANCE; NAUSEA; PRIORITY JOURNAL; PROMOTER REGION; SINGLE DRUG DOSE; VOMITING;

ADULT; AGED; AREA UNDER CURVE; CIRCADIAN RHYTHM; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENES, MDR; GLUCURONOSYLTRANSFERASE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POLYMORPHISM, GENETIC;

EID: 33747873522     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000231874.53240.ba     Document Type: Article

References (37)

1. Holzberg D, Albrecht U. The circadian clock: a manager of biochemical processes within the organism. J Neuroendocrinol 2003; 15: 339.
2. Chacon F, Cano P, Lopez-Varela S, et al. Chronobiological features of the immune system. Effect of calorie restriction. Eur J Clin Nutr 2002; 56: S69.
3. Born J, Lange T, Hansen K, et al. Effects of sleep and circadian rhythm on human circulating immune cells. J Immunol 1997; 158: 4454.
4. Reinberg A, Halberg F. Circadian chronopharmacology. Annu Rev Pharmacol 1971; 11: 455.
5. Lemmer B. Relevance for chronopharmacology in practical medicine. Semin Perinatol 2000; 24: 280.
6. Chateauvert N, Cote H. Circadian variations in the pharmacokinetics of a new microemulsion formulation of cyclosporine in cardiac transplant recipients. Pharmacotherapy 1998; 18: 364.
7. Min DI, Chen HY, Fabrega A, et al. Circadian variation of tacrolimus disposition in liver allograft recipients. Transplantation 1996; 62: 1190.
8. Tada H, Satoh S, Iinuma M, et al. Chronopharmacokinetics of tacrolimus in kidney transplant recipients: occurrence of acute rejection. J Clin Pharmacol 2003; 43: 859.
9. Cox VC, Ensom MH. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit 2003; 25: 137.
10. Iwase T, Kajimura N, Uchiyama M, et al. Mutation screening of the human Clock gene in circadian rhythm sleep disorders. Psychiatry Res 2002; 109: 121.
11. Mishima K, Tozawa T, Satoh K, et al. The 3111T/C polymorphism of hClock is associated with evening preference and delayed sleep timing in a Japanese population sample. Am J Med Genet B Neuropsychiatr Genet 2005; 133B: 101.
12. Papadimitriou JC, Cangro CB, Lustberg A, et al. Histologic features of mycophenolate mofetil-related colitis: a graft-verst-host disease-like pattern. Int J Surg Pathol 2003; 11: 295.
13. Owens IS, Ritter JK, Yeatman MT, Chen F. The novel UGT1 gene complex links bilirubin, xenobiotics, and therapeutic drug metabolism by encoding UDP-glucuronosyltransferase isozymes with a common carboxyl terminus. J Pharmacokinet Biopharm 1996; 24: 491.
14. Bernard O, Guillemette C. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos 2004; 32: 775.
15. Marsh S, McLeod HL. Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 2004; 5: 835.
16. Dirks NL, Huth B, Yates CR, Meibohm B. Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. Int J Clin Pharmacol Ther 2004; 42: 701.
17. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359: 30.
18. Kobayashi M, Saitoh H, Kobayashi M, et al. Cyclosporin A, but no tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther 2004; 309: 1029.
19. Albermann N, Schmitz-Winnenthal FH, Z'graggen K, et al. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Phamrcol 2005; 70: 949.
20. Seebacher G, Weigel G, Wolner E, et al. A simple HPLC method for monitoring mycophenolic acid and its glucuronidated metabolite in transplant recipients. Clin Chem Lab Med 1999; 37: 409.
21. Premawardhena A, Fisher CA, Liu YT, et al. The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications. Blood Cells Mol Dis 2003; 31: 98.
22. Tsuchiya N, Satoh S, Tada H, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004; 78: 1182.
23. Lemmer B, Bruguerolle B. Chronopharmacokinetics Are they clinically relevant? Clin Pharmacokinet 1994; 26: 419.
24. Bullingham R, Shah J, Goldblum R, Schiff M. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Br J Clin Pharmacol 1996; 41: 513.
25. Undre NA. Pharmacokinetics of tacrolimus-based combination therapies. Nephrol Dial Transplant 2003; 18: Suppl 1: i12.
26. Kuriata-Kordek M, Boratynska M, Falkiewicz K, et al. The influence of calcineurin inhibitors on mycophenolic acid pharmacokinetics. Transplant Proc 2003; 35: 2369.
27. Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 2005; 5: 987.
28. Cattaneo D, Perico N, Gaspari F, et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002; 62: 1060.
29. Desan PH, Oren DA, Malison R, et al. Genetic polymorphism at the Clock gene locus and major depression. Am J Med Genet 2000; 96: 418.
30. Kelly P, Kahan BD: Review: metabolism of immunosuppressant drugs Curr Drug Metab 2002; 3: 275.
31. Jirasiritham S, Sumethkul V, Mavichak V, Na-Bangchang K. The pharmacokinetics of mycophenolate mofetil in Thai Kidney transplant recipients. Transplant Proc 2004; 36: 2076.
32. Pape L, Ehrich JH, Offner G. Long-term follow-up of pediatric transplant recipients: mycophenolic acid trough levels are not a good indicator for long-term graft function. Clin Tranplant 2004; 18: 576-579.
33. Toffoli G, Cecchin E, Corona G, Boiocchi M. Pharmacogenetics of irinotecan Cur Med Chem Anti-Canc Agents 2003; 3: 225.
34. Miles KK, Stern ST, Smith PC, et al. An investigation of human and rat liver microsomal mycophenolic acid glucuronidation: evidence for a principal role of ugt1a enzymes and species differences in ugt1a specificity. Drug Metab Dispos 2005; 33: 1513.
35. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473.
36. Mills JB, Rose KA, Sadagopan N, et al. Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J Pharmacol Exp Ther 2004; 309: 303.
37. Chen C, Mireles RJ, Campbell SD, et al. Differential interaction of 3-hydroxy-3-methlglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos 2005; 33: 537.